Copyright
©The Author(s) 2024.
World J Clin Oncol. Jan 24, 2024; 15(1): 23-31
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.23
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.23
Drug | Target | Action |
Ipilimumab | CTLA-4 | Blocking the CTLA-4 receptor, enhancing T-cell activation, amplifying T-cell-mediated immunity |
Tremelimumab | CTLA-4 | Blocking the CTLA-4 receptor, amplifying T-cell-mediated immunity |
Nivolumab | PD-1 | Activation of T cell-mediated response. Lysis and degradation of cancer cells |
Pembrolizumab | PD-1 | Activation of T cell-mediated response. Lysis and degradation of cancer cells |
Coxsackievirus A21 (V937) | Augmented T-cell responses with consequent improved clinical activity | |
Lymphocyte-activation gene 3 | Negatively regulation T-cell proliferation and effector T-cell function | |
Tebentafusp | T-cell-redirecting bispecific fusion proteins | Enhancing HLA-A*0201-restricted T-cell receptor specifically recognizing the glycoprotein 100 |
- Citation: Sorrentino FS, De Rosa F, Di Terlizzi P, Toneatto G, Gabai A, Finocchio L, Salati C, Spadea L, Zeppieri M. Uveal melanoma: Recent advances in immunotherapy. World J Clin Oncol 2024; 15(1): 23-31
- URL: https://www.wjgnet.com/2218-4333/full/v15/i1/23.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i1.23